Clinical Trial News and Research

RSS

Cardiac biomarkers aid microvascular risk prediction in diabetics

Assessing cardiac biomarkers results in a moderate improvement in the ability to predict microvascular complications in patients with Type 2 diabetes, say researchers.

6 Jun 2014

Gene networks may offer attractive targets for developing new autism drugs

A large new analysis of DNA from thousands of patients has uncovered several underlying gene networks with potentially important roles in autism.

6 Jun 2014

European Commission approves Boehringer Ingelheim's Pradaxa for prevention of DVT and PE

Boehringer Ingelheim today announces that Pradaxa (dabigatran etexilate) has been approved by the European Commission for the treatment and prevention of recurrence of deep vein thrombosis (DVT) and pulmonary embolism (PE).

6 Jun 2014

New drug shows promising results in patients with advanced pancreatic cancer

A clinical trial conducted by researchers at the Virginia G. Piper Cancer Center Clinical Trials, a partnership between Scottsdale Healthcare and the Translational Genomics Research Institute, showed that a new drug called MM-398, given in combination with 5-flourouracil (5FU) and leucovorin, produced a significant overall survival rate in patients with advanced, previously-treated pancreatic cancer.

6 Jun 2014

Improved glycemic control can slow progression of ESRD in type 1 diabetic people

People with type 1 diabetes who have developed kidney complications can slow the progression of their complications by improving control of their glycemic (blood glucose) levels over the long term.

6 Jun 2014

Merck enrolls first patient in reformulated raltegravir Phase 3 trial for treatment of HIV-1 infection

Merck, known as MSD outside the United States and Canada, today announced that the first patient has been enrolled in the company's global Phase 3 clinical trial, ONCEMRK.

6 Jun 2014

Tolero Pharmaceuticals reports positive interim results from alvocidib Phase 2 trial for AML treatment

Tolero Pharmaceuticals, Inc., a late clinical-stage biopharmaceutical company developing treatments for oncology and blood disorders, reported positive interim results from an ongoing, randomized Phase 2 clinical trial of its lead drug candidate, alvocidib, in combination with cytarabine plus mitoxantrone for previously untreated acute myeloid leukemia (AML) patients.

6 Jun 2014

Study offers clues to best long-acting injectable antipsychotic use

Findings from the PROACTIVE study suggest why the benefits of long-acting injectable second-generation antipsychotics may be difficult to detect in a clinical trial.

5 Jun 2014

Immune Design begins treatment in LV305 Phase 1 clinical trial for cancer

Immune Design, a clinical-stage immunotherapy company focused on the development of novel immune-based therapies for cancer and other chronic conditions, today announced treatment of the first patient in a Phase 1 clinical trial of LV305, an immuno-oncology investigational agent from the company's DCVexTM lentiviral vector platform.

5 Jun 2014

Edge Therapeutics commences enrollment in second cohort of EG-1962 Phase 1/2 NEWTON study for aSAH

Edge Therapeutics, a clinical-stage biotechnology company that discovers, develops and seeks to commercialize novel, hospital-based therapies for acute, life-threatening neurological conditions, today announced that it has initiated patient enrollment in the second cohort of the NEWTON study, a multicenter, randomized, controlled, open-label, Phase 1/2 clinical trial of the company's lead product candidate, EG-1962.

5 Jun 2014

Advanced Cancer Therapeutics begins clinical trials of PFK-158 small molecule therapeutic candidate

Advanced Cancer Therapeutics, a privately held company dedicated to bringing new anti-cancer therapies to market, announced today (June 4) that it has begun clinical trials of PFK-158, a small molecule therapeutic candidate that inactivates a novel cancer metabolism target never before examined in human clinical trials.

5 Jun 2014

Navigated brain stimulation system may help improve motor function for people recovering from stroke

Researchers at Shepherd Center are studying whether stimulating the brain before rehabilitation could yield greater gains in motor function for people recovering from stroke.

5 Jun 2014

$SAGE reports preliminary data from SAGE-547 Phase 1/2 clinical trial for super-refractory status epilepticus$

SAGE reports preliminary data from SAGE-547 Phase 1/2 clinical trial for super-refractory status epilepticus

SAGE Therapeutics, a biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, today announced preliminary data from its ongoing open-label Phase 1/2 clinical trial of SAGE-547, an allosteric modulator of GABAA receptors, in patients with super-refractory status epilepticus (SRSE).

5 Jun 2014

Interim data from Promedior’s PRM-151 Phase 2 myelofibrosis clinical trial to be presented at 19th EHA Congress

Promedior, Inc., a clinical stage biotechnology company developing novel therapeutics for the treatment of fibrosis, today announced that Ruben Mesa, MD, will present interim data from the Company's ongoing Phase 2 clinical trial of its lead product candidate, PRM-151, for the treatment of myelofibrosis, in a poster presentation on June 14, 2014 at the 19th Congress of European Hematology Association (EHA) which is being held in Milan, Italy, from June 12-15, 2014.

5 Jun 2014

Symphony continuous glucose monitoring system study selected for presentation at ADA scientific sessions

Echo Therapeutics, Inc., a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, is pleased to announce that its most recently completed clinical study of Symphony was selected for poster presentation at the 74th Scientific Sessions of the American Diabetes Association (ADA) which will be held June 13-17, 2014 in San Francisco, CA.

5 Jun 2014

NEJM publishes results from SOLO I Phase 3 clinical trial of ORBACTIV for ABSSSI

The Medicines Company today announced the publication of the results from the SOLO I Phase 3 clinical trial of ORBACTIV (oritavancin), an investigational intravenous antibiotic treatment for Acute Bacterial Skin and Skin Structure Infections (ABSSSI), in the New England Journal of Medicine.

5 Jun 2014

Palliative support services help caregivers of patients with advanced cancer

Dartmouth researchers have found that those caring for patients with advanced cancer experienced reduced depression and felt less burdened by caregiving tasks when palliative support services were offered soon after the patient's diagnosis.

5 Jun 2014

New antibiotic proves effective in treating serious bacterial skin and skin-structure infections

A study published in today's New England Journal of Medicine reports that the antibiotic dalbavancin is as effective as vancomycin, the current standard-of-care antibiotic used to treat serious bacterial skin and skin-structure infections.

5 Jun 2014

Leukemia researcher wins 2014 Taubman Prize for Excellence in Translational Medical Science

A physician-scientist who developed a personalized immunotherapy for leukemia using patients' own T cells is the recipient of the 2014 Taubman Prize for Excellence in Translational Medical Science, awarded by the A. Alfred Taubman Medical Research Institute at the University of Michigan Medical School.

4 Jun 2014

Glenmark Pharmaceuticals opens new monoclonal antibody manufacturing facility in Switzerland

Glenmark Pharmaceuticals S.A (GPSA), a wholly-owned subsidiary of Glenmark Pharmaceuticals Limited, India (GPL), announced the opening of its new cGMP compliant monoclonal antibody manufacturing facility in La Chaux-de-Fonds, Switzerland. T

4 Jun 2014

Clinical Trial News and Research

Cardiac biomarkers aid microvascular risk prediction in diabetics

Gene networks may offer attractive targets for developing new autism drugs

European Commission approves Boehringer Ingelheim's Pradaxa for prevention of DVT and PE

New drug shows promising results in patients with advanced pancreatic cancer

Improved glycemic control can slow progression of ESRD in type 1 diabetic people

Merck enrolls first patient in reformulated raltegravir Phase 3 trial for treatment of HIV-1 infection

Tolero Pharmaceuticals reports positive interim results from alvocidib Phase 2 trial for AML treatment

Study offers clues to best long-acting injectable antipsychotic use

Immune Design begins treatment in LV305 Phase 1 clinical trial for cancer

Edge Therapeutics commences enrollment in second cohort of EG-1962 Phase 1/2 NEWTON study for aSAH

Advanced Cancer Therapeutics begins clinical trials of PFK-158 small molecule therapeutic candidate

Navigated brain stimulation system may help improve motor function for people recovering from stroke

SAGE reports preliminary data from SAGE-547 Phase 1/2 clinical trial for super-refractory status epilepticus

Interim data from Promedior’s PRM-151 Phase 2 myelofibrosis clinical trial to be presented at 19th EHA Congress

Symphony continuous glucose monitoring system study selected for presentation at ADA scientific sessions

NEJM publishes results from SOLO I Phase 3 clinical trial of ORBACTIV for ABSSSI

Palliative support services help caregivers of patients with advanced cancer

New antibiotic proves effective in treating serious bacterial skin and skin-structure infections

Leukemia researcher wins 2014 Taubman Prize for Excellence in Translational Medical Science

Glenmark Pharmaceuticals opens new monoclonal antibody manufacturing facility in Switzerland

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer